Marketing Authorization (MA) for a New Drug
Marketing Authorization (MA) is an essential step for any drug before its commercialization. Without this authorization, it is impossible to make a therapeutic product available to patients, whether it is an innovative drug or a generic medication. MA can be granted at the national level (by the ANSM in France) or at the European level (through the EMA or a national authority). This MA procedure certifies, based on a comprehensive dossier, that the drug has undergone relevant studies ensuring its safety, quality, and efficacy.
Within the European Union, four procedures stand out:
- National procedure (MA is granted for a single country)
- Centralized procedure (MA is valid across all European Union countries)
- Mutual recognition procedure (a national MA is subsequently recognized by several other countries chosen by the laboratory submitting the MA application)
- Decentralized procedure (MA is granted simultaneously for multiple countries selected by the laboratory applying)
What is the purpose of Marketing Authorization?
MA refers to an administrative and health decision that establishes a safety framework for each drug. A competent health authority, such as the ANSM in France, reviews the application and evaluates the dossier based on scientific criteria. This authority ensures that, following the evaluation, the drug meets very strict criteria regarding:
- Safety: The drug’s safety must be demonstrated through pharmacokinetic studies and the assessment of potential adverse effects (known as pharmacovigilance).
- Quality: Industrial manufacturing must adhere to proven standards and be subject to continuous monitoring.
- Efficacy: The drug’s effectiveness must be proven through clinical studies validating a tangible benefit for the targeted patient.
In all EU countries, drug commercialization requires MA. This certification ensures that the drug can be prescribed under the conditions defined by the authorization. It also establishes a Summary of Product Characteristics (SmPC), accessible to all healthcare professionals.
Read also: Methods for accelerating the drug development process
The Different Routes to Obtain MA
Pharmaceutical companies can choose from several routes to obtain MA, depending on the type of drug, development stages, and target geographical area. The four main procedures are:
- National procedure:
MA is granted for a single country by the national health agency (ANSM in France) and is only valid within that country. - Centralized procedure:
MA is granted by the European Commission after assessment by the EMA (European Medicines Agency). This route is mandatory for certain innovative drugs, such as biotechnological products. - Mutual recognition procedure:
This involves recognizing an MA already granted in one EU member state. Other selected countries align with the initial decision. - Decentralized procedure:
This applies when a drug has not yet obtained MA in the EU. The agency of the reference member state coordinates the evaluation for the other member states.
In all these cases, the authorization process includes dossier submission, scientific evaluation, and final validation. A decision is typically issued within 210 days. The centralized, mutual recognition, and decentralized procedures are particularly relevant when a laboratory aims to enter multiple European markets simultaneously.
Read also : What are the differences in market authorization between the FDA and EMA ?
Essential Criteria: Safety, Efficacy, and Quality
MA is granted based on a favorable benefit-risk assessment. Authorities examine tolerance data and therapeutic relevance, ensuring that:
- The drug is safe and well-tolerated.
- Its manufacturing process is robust and consistent.
- Its efficacy is clinically demonstrated for the intended indications.
If the benefit/risk balance is positive, MA may be granted. Otherwise, an Early Access (EA) or Compassionate Use (CU) exemption may be considered. This limited provision applies in urgent medical situations where no approved treatment exists. Accelerated approvals generally concern severe diseases where the absence of a solution poses significant risks.
Which Drugs Require MA?
- Human-use drugs
- Veterinary medicines for animals
- Generic drugs
All these require an MA application and approval. The only exceptions concern temporary use (such as early access programs, formerly ATU) or other exceptional cases where off-label use may be authorized. However, the general rule remains: no MA, no legal commercialization or distribution of the drug.
Key Steps Between Evaluation and Authorization Granting
The major steps in the drug marketing process include:
- Dossier preparation (Common Technical Document – CTD): The pharmaceutical company compiles all required data.
- Submission to a national or European health agency: The applicant formally submits the registration dossier.
- Review process: The health agency conducts a scientific assessment, provides feedback, or requests additional information.
- Decision: MA is either granted, denied, or issued with specific conditions.
- Implementation timeframe: Once validated, the MA holder can commercialize the drug under the defined conditions.
Post-MA: Modifications, Renewal, and Monitoring
Obtaining MA does not mark the end of regulatory obligations. The MA holder must comply with all conditions outlined in the SmPC and ensure continuous monitoring. Any modifications (new indications, new dosage forms, etc.) must be approved by health authorities.
The initial MA duration is typically five years, after which renewal may be required. If no major safety concerns arise, MA can become permanent. However, stricter monitoring may be imposed if risks persist or the active substance needs reassessment.
Conclusion and Future Perspectives
MA is a key certification in the pharmaceutical ecosystem, ensuring that marketed drugs are safe, effective, and of high quality. Under the supervision of competent authorities such as the ANSM or EMA, pharmaceutical companies must submit a complete dossier for approval. Each procedure (national, mutual recognition, decentralized, or centralized) follows well-defined rules requiring meticulous CTD examination and ongoing monitoring.
This regulatory framework strikes a balance between public health safety and pharmaceutical innovation. MA serves as the official validation that a proposed treatment meets the highest standards of efficacy and safety, ensuring that patients receive reliable and high-quality medications.
